Optimizing Hormone Therapy in Women with Premature Ovarian Insufficiency to Maintain Bone Mass

Use of an oral contraceptive with 30 µg of ethinyl estradiol or high-dose oral estrogen was more effective than low-dose HT.

In premature ovarian insufficiency (POI), ovarian function ceases prior to age 40. For women with POI, excess risk for osteoporosis or fractures is a major concern. Hormone therapy (HT) represents a mainstay of treatment for these women; however, which approach to HT most effectively maintains bone mineral density (BMD) remains uncertain.

In a retrospective, observational, longitudinal study, investigators at a Brazilian academic center evaluated BMD outcomes of several HT regimens in 119 POI patients (mean age, 30), who had undergone two or more BMD assessments at intervals of 2 years. Use of an oral contraceptive with 30 µg ethinyl estradiol and levonorgestrel (COC) was compared with a low-dose estrogen and progestin combination (EPT, 0.62…

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Optimizing Hormone Therapy in Women with Premature Ovarian Insufficiency to Maintain Bone Mass

Topics

Reviewing Author